moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Company profile
Ticker
MRNA, MRNA-MM
Exchange
Website
CEO
Stephane Bancel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Moderna Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Moderna Australia Pty Ltd • Moderna Biopharma Canada Corporation • Moderna Biotech Distributor UK Ltd. • Moderna Biotech Kenya Manufacturing Ltd. • Moderna Biotech Manufacturing UK Ltd. • Moderna Biotech Securities, Inc. • Moderna Biotech Singapore Pte. Ltd. • Moderna Biotech UK Limited • Moderna Charitable Foundation, Inc. • Moderna Denmark ApS ...
IRS number
813467528
MRNA stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
21 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
ARS
2023 FY
Annual report to shareholders
15 Mar 24
PRE 14A
Preliminary proxy
11 Mar 24
S-8
Registration of securities for employees
23 Feb 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
22 Feb 24
8-K
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24
8-K
Departure of Directors or Certain Officers
12 Dec 23
8-K
Regulation FD Disclosure
6 Nov 23
Transcripts
MRNA
Earnings call transcript
2023 Q4
22 Feb 24
MRNA
Earnings call transcript
2023 Q3
2 Nov 23
MRNA
Earnings call transcript
2023 Q2
3 Aug 23
MRNA
Earnings call transcript
2023 Q1
4 May 23
MRNA
Earnings call transcript
2022 Q4
23 Feb 23
MRNA
Earnings call transcript
2022 Q3
3 Nov 22
MRNA
Earnings call transcript
2022 Q2
3 Aug 22
MRNA
Earnings call transcript
2022 Q1
4 May 22
MRNA
Earnings call transcript
2021 Q4
24 Feb 22
MRNA
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
144
Notice of proposed sale of securities
24 Apr 24
4
NOUBAR AFEYAN
19 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
4
Stephen Hoge
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
NOUBAR AFEYAN
12 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
SC 13G/A
VANGUARD GROUP INC
10 Apr 24
4
James M Mock
9 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.95 bn | 2.95 bn | 2.95 bn | 2.95 bn | 2.95 bn | 2.95 bn |
Cash burn (monthly) | 289.67 mm | 7.33 mm | 670.67 mm | 215.83 mm | 533.33 mm | 173.17 mm |
Cash used (since last report) | 1.99 bn | 50.47 mm | 4.62 bn | 1.49 bn | 3.67 bn | 1.19 bn |
Cash remaining | 959.24 mm | 2.90 bn | -1.66 bn | 1.47 bn | -717.90 mm | 1.76 bn |
Runway (months of cash) | 3.3 | 395.8 | -2.5 | 6.8 | -1.3 | 10.2 |
Institutional ownership, Q3 2023
70.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 865 |
Opened positions | 95 |
Closed positions | 156 |
Increased positions | 341 |
Reduced positions | 284 |
13F shares | Current |
---|---|
Total value | 25.15 tn |
Total shares | 269.59 mm |
Total puts | 10.38 mm |
Total calls | 12.84 mm |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Baillie Gifford & Co | 45.65 mm | $4.72 tn |
Vanguard | 27.66 mm | $2.86 tn |
BLK Blackrock | 24.74 mm | $2.56 tn |
Flagship Ventures Fund IV General Partner | 17.58 mm | $0.00 |
STT State Street | 13.95 mm | $1.44 tn |
Flagship Pioneering | 9.67 mm | $998.41 bn |
Bancel Stephane | 9.05 mm | $0.00 |
Theleme Partners | 6.90 mm | $712.45 bn |
Geode Capital Management | 6.42 mm | $661.02 bn |
Wellington Management | 5.61 mm | $579.57 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 104.4896 | 282 | 29.47 k | 2,056,931 |
17 Apr 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 103.6908 | 6,475 | 671.40 k | 2,057,213 |
17 Apr 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 103.0983 | 8,243 | 849.84 k | 2,063,688 |
15 Apr 24 | Stephen Hoge | Common Stock | Sell | Dispose S | No | Yes | 105.02 | 15,000 | 1.58 mm | 1,486,241 |
10 Apr 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 109.3628 | 389 | 42.54 k | 2,071,931 |
10 Apr 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 108.5631 | 748 | 81.21 k | 2,072,320 |
10 Apr 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 107.3131 | 7,512 | 806.14 k | 2,073,068 |
10 Apr 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 106.5945 | 6,351 | 676.98 k | 2,080,580 |
8 Apr 24 | Mock James M | Common Stock | Sell | Dispose S | No | No | 101.9281 | 705 | 71.86 k | 5,048 |
5 Apr 24 | Mock James M | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,453 | 0.00 | 5,753 |
News
What's Going On With Pfizer Stock On Thursday?
25 Apr 24
How Is The Market Feeling About Moderna?
25 Apr 24
Moderna And OpenAI Collaborate To Advance mRNA Medicine
24 Apr 24
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
23 Apr 24
Moderna Options Trading: A Deep Dive into Market Sentiment
22 Apr 24
Press releases
Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
25 Apr 24
Moderna and OpenAI Collaborate To Advance mRNA Medicine
24 Apr 24
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
22 Apr 24
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
17 Apr 24
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
8 Apr 24